Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Sabra Health Care REIT, Inc. (SBRA) has a Wall Street consensus price target of $21.33, based on estimates from 29 covering analysts. With the stock currently trading at $20.55, this represents a potential upside of +3.8%. The company has a market capitalization of $5.17B.
Analyst price targets range from a low of $21.00 to a high of $22.00, representing a 5% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 11 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SBRA trades at a forward P/E of 29.3x. Analysts expect EPS to grow +14.3% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SBRA stacks up against sector leader Welltower Inc..
Start ComparisonThe consensus price target for SBRA is $21.33, close to the current price of $20.55 (3.8% implied move). Based on 29 analyst estimates, the stock appears fairly valued near current levels.
SBRA has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $21.33 implies 3.8% upside from current levels.
SBRA trades at a forward P/E of 29.3446x, representing a moderate valuation. With analysts targeting $21.33 (3.8% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $22 for SBRA, while the most conservative target is $21. The consensus of $21.33 represents the median expectation. These targets typically reflect 12-month expectations.
SBRA is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 16 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SBRA stock forecast based on 29 Wall Street analysts shows a consensus price target of $21.33, with estimates ranging from $21 (bear case) to $22 (bull case). The median consensus rating is "Hold".
SBRA trades at a forward P/E ratio of 29.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SBRA appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $21.33 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SBRA analyst price targets range from $21 to $22, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.33 consensus represents the middle ground.